Cover Image
市場調查報告書

Biocon Limited : 產品平台分析

Biocon Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224592
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
Biocon Limited : 產品平台分析 Biocon Limited - Product Pipeline Review - 2016
出版日期: 2016年09月30日 內容資訊: 英文 51 Pages
簡介

Biocon Limited是巷完全一體型,創新主導之新興的全球性生物製藥公司,專門針對生物醫藥品和調查業務產業。該公司製造廣泛的醫藥品有效成分(APIs),品牌製劑,生技藥品,以因應各種疾病。

本報告提供Biocon Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Biocon Limited的基本資料

Biocon Limited概要

  • 主要資訊
  • 企業資料

Biocon Limited:R&D概要

  • 主要的治療範圍

Biocon Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Biocon Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第Ⅲ階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Biocon Limited:藥物簡介

  • (rosuvastatin calcium + ezetimibe)
  • (rosuvastatin calcium + olmesartan medoxomil)
  • adalimumab biosimilar
  • bevacizumab biosimilar
  • insulin glargine
  • pegfilgrastim
  • trastuzumab biosimilar
  • insulin human
  • BVX-20
  • itolizumab
  • etanercept biosimilar
  • insulin aspart
  • insulin lispro
  • Monoclonal Antibody for Oncology and Infectious Disease

Biocon Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Biocon Limited:最近的開發平台趨勢

Biocon Limited:暫停中的計劃

Biocon Limited:企業發表

Biocon Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08137CDB

Summary

Global Markets Direct's, 'Biocon Limited - Product Pipeline Review - 2016', provides an overview of the Biocon Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited
  • The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Biocon Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Biocon Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Biocon Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Biocon Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Biocon Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biocon Limited Snapshot
    • Biocon Limited Overview
    • Key Facts
  • Biocon Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Biocon Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Biocon Limited - Pipeline Products Glance
    • Biocon Limited - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Biocon Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Biocon Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Biocon Limited - Drug Profiles
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bevacizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVX-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • insulin aspart - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • insulin glargine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • insulin human - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • insulin lispro - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • insulin tregopil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Oncology and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trastuzumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Biocon Limited - Pipeline Analysis
    • Biocon Limited - Pipeline Products by Target
    • Biocon Limited - Pipeline Products by Route of Administration
    • Biocon Limited - Pipeline Products by Molecule Type
    • Biocon Limited - Pipeline Products by Mechanism of Action
  • Biocon Limited - Dormant Projects
  • Biocon Limited - Company Statement
  • Biocon Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biocon Limited, Key Facts
  • Biocon Limited - Pipeline by Indication, 2016
  • Biocon Limited - Pipeline by Stage of Development, 2016
  • Biocon Limited - Monotherapy Products in Pipeline, 2016
  • Biocon Limited - Partnered Products in Pipeline, 2016
  • Biocon Limited - Partnered Products/ Combination Treatment Modalities, 2016
  • Biocon Limited - Pre-Registration, 2016
  • Biocon Limited - Phase III, 2016
  • Biocon Limited - Phase II, 2016
  • Biocon Limited - Phase I, 2016
  • Biocon Limited - Preclinical, 2016
  • Biocon Limited - Pipeline by Target, 2016
  • Biocon Limited - Pipeline by Route of Administration, 2016
  • Biocon Limited - Pipeline by Molecule Type, 2016
  • Biocon Limited - Pipeline Products by Mechanism of Action, 2016
  • Biocon Limited - Dormant Developmental Projects,2016
  • Biocon Limited, Other Locations
  • Biocon Limited, Subsidiaries

List of Figures

  • Biocon Limited - Pipeline by Top 10 Indication, 2016
  • Biocon Limited - Pipeline by Stage of Development, 2016
  • Biocon Limited - Monotherapy Products in Pipeline, 2016
  • Biocon Limited - Partnered Products in Pipeline, 2016
  • Biocon Limited - Pipeline by Target, 2016
  • Biocon Limited - Pipeline by Route of Administration, 2016
  • Biocon Limited - Pipeline by Molecule Type, 2016
  • Biocon Limited - Pipeline Products by Mechanism of Action, 2016
Back to Top